Abstract
Purpose of Review: The polypill, referring to a variety of combinations of low-cost cardiovascular and stroke preventive medications combined in a single tablet, has been evaluated as a population-based approach for cardiovascular disease prevention in several trials. This review summarizes the scope of the problem, main trial results, and their potential applicability to the US population. Recent Findings: Initial trials demonstrated the efficacy of the polypill approach. The most recent, the PolyIran study, showed the effectiveness of one form of a polypill for cardiovascular disease prevention, high medication adherence, and low adverse event rates. Summary: None of published polypill trials focused on stroke as the primary outcome and most were conducted in developing countries, limiting generalization to the US population. A US-based randomized trial with stroke as the primary outcome is needed to assess the usefulness of this approach for stroke prevention in the USA.
Original language | English |
---|---|
Article number | 10 |
Journal | Current Neurology and Neuroscience Reports |
Volume | 20 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2020 |
Bibliographical note
Publisher Copyright:© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Keywords
- Clinical trial
- Drug combinations
- Polypill
- Primary prevention
- Secondary prevention
- Stroke
ASJC Scopus subject areas
- General Neuroscience
- Clinical Neurology